AR058591A1 - Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido - Google Patents

Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido

Info

Publication number
AR058591A1
AR058591A1 ARP060105668A ARP060105668A AR058591A1 AR 058591 A1 AR058591 A1 AR 058591A1 AR P060105668 A ARP060105668 A AR P060105668A AR P060105668 A ARP060105668 A AR P060105668A AR 058591 A1 AR058591 A1 AR 058591A1
Authority
AR
Argentina
Prior art keywords
microparticles
tumors
octreotide
polymers
pharmaceutically acceptable
Prior art date
Application number
ARP060105668A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR058591A1 publication Critical patent/AR058591A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Abstract

La presente se refiere a composiciones de liberacion sostenida que comprenden, como ingrediente activo, octreotida o una sal farmacéuticamente aceptable de la misma y dos o más diferentes polímeros de poliláctido-co-glicolido (PLGAs). Reivindicacion 20: El uso de una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 19 para una terapia de mantenimiento a largo plazo en pacientes acromegálicos, y tratamiento de diarrea severa y brote asociado con tumores carcinoides malignos y tumores de péptido intestinales vasoactivos (tumores vipoma). Reivindicacion 21: Un método para administrar octreotida o una sal farmacéuticamente aceptable de la misma para una terapia de mantenimiento a largo plazo en pacientes acromegálicos, y tratamiento de diarrea severa y brote asociado con tumores carcinoides malignos y tumores de péptido intestinales vasoactivos /tumores vipoma), dicho método comprende administrar, a un paciente con la necesidad de octreotida o una sal farmacéuticamente aceptable de la misma, una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 19. Reivindicacion 22: Un procedimiente para la fabricacion de micropartículas de acuerdo con la reivindicacion 14, que comrpende: (i) la preparacion de una fase orgánica interna que comprende: (ia) disolver el polímero o polímeros en un solvente orgánico adecuado o mezcla de solventes; (ib) disolver/suspender/emulsificar la substancia de fármaco en la solucion de polímero obtenida en el paso (ia); (ii) la preparacion de una fase acuosa externa conteniendo estabilizadores; (iii) mezclar la fase orgánica interna con una fase acuosa externa para formar una emulsion; y (iv) endurecer las micropartículas a través de evaporacion del solvente o extraccion del solvente, lavar las micropartículas, secar las micropartículas y tamizar las micropartículas a través de 140 micrometros. reivindicacion 23: Un equipo de administracion que comprende la composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 19 en un frasco, junto con un vehículo a base de agua en una ampolla, frasco o jeringa pre-llenada o como micropartículas y vehículo separado en una jeringa de cámara doble.
ARP060105668A 2005-12-22 2006-12-20 Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido AR058591A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
EP06119086 2006-08-17

Publications (1)

Publication Number Publication Date
AR058591A1 true AR058591A1 (es) 2008-02-13

Family

ID=37772904

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105668A AR058591A1 (es) 2005-12-22 2006-12-20 Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido

Country Status (22)

Country Link
US (6) US20090004283A1 (es)
EP (3) EP2359809B1 (es)
JP (4) JP2009520727A (es)
KR (5) KR101245919B1 (es)
CN (1) CN103251929A (es)
AR (1) AR058591A1 (es)
AU (1) AU2006328950B2 (es)
BR (2) BR122019027412B8 (es)
CA (1) CA2631811C (es)
CL (1) CL2018003398A1 (es)
EC (1) ECSP088560A (es)
ES (2) ES2755032T3 (es)
IL (1) IL191842A0 (es)
IN (1) IN2015DN03936A (es)
MA (1) MA30064B1 (es)
NO (1) NO20082988L (es)
PE (1) PE20071139A1 (es)
PL (2) PL1968549T3 (es)
PT (2) PT1968549E (es)
RU (1) RU2464972C2 (es)
TW (2) TWI469788B (es)
WO (1) WO2007071395A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431077A1 (en) 2007-06-06 2019-01-23 Debiopharm Research & Manufacturing SA Slow release pharmaceutical composition made of microparticles
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
WO2009095450A1 (en) * 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
WO2010085609A2 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
EP2595604B1 (en) * 2010-07-21 2016-03-30 Allergan, Inc. Method of controlling initial drug release of sirna from sustained-release implants
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
WO2012083026A1 (en) * 2010-12-15 2012-06-21 Evonik Degussa Corporation Branched polyol polyesters, blends and pharmaceutical formulations comprising same
BR112013027235B1 (pt) 2011-04-25 2021-11-16 Shan Dong Luye Pharmaceutical Co., Ltd Composição farmacêutica, seu uso, e formulação de microsferas para injeção de liberação sustentada
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
EP3253401A4 (en) 2015-02-03 2018-11-21 Chiasma Inc. Method of treating diseases
WO2016208685A1 (ja) * 2015-06-26 2016-12-29 オリンパス株式会社 内視鏡電源供給システム
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
KR20220163418A (ko) * 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11617720B2 (en) 2020-05-08 2023-04-04 M. Technique Co., Ltd. Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same
KR20220163416A (ko) 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CY1327A (en) 1979-11-27 1986-06-27 Sandoz Ag Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
IL133105A (en) * 1997-06-04 2004-09-27 Debio Rech Pharma Sa Implants for controlled release of pharmaceutically active principles and method for making same
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
ATE374598T1 (de) * 2002-03-15 2007-10-15 Alrise Biosystems Gmbh Mikropartikel und verfahren zur deren herstellung
MXPA05004927A (es) * 2002-11-06 2005-09-08 Alza Corp Formulaciones de deposito de liberacion controlada.
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
CA2533314C (en) * 2003-07-18 2013-07-09 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
EP1786400B1 (en) * 2004-08-12 2009-03-11 Quest Pharmaceutical Services Pharmaceutical compositions for controlled release delivery of biologically active compounds

Also Published As

Publication number Publication date
KR101245919B1 (ko) 2013-03-20
CA2631811C (en) 2017-06-20
BRPI0620063A2 (pt) 2011-11-01
JP2015044823A (ja) 2015-03-12
KR20130024988A (ko) 2013-03-08
TWI468172B (zh) 2015-01-11
JP2013177406A (ja) 2013-09-09
US20150037420A1 (en) 2015-02-05
KR20130024987A (ko) 2013-03-08
EP2359809B1 (en) 2019-08-14
US20160120935A1 (en) 2016-05-05
CA2631811A1 (en) 2007-06-28
NO20082988L (no) 2008-08-29
PT2359809T (pt) 2019-11-04
PT1968549E (pt) 2014-08-29
EP1968549A1 (en) 2008-09-17
IN2015DN03936A (es) 2015-10-02
JP6239851B2 (ja) 2017-11-29
JP2009520727A (ja) 2009-05-28
ES2755032T3 (es) 2020-04-21
TWI469788B (zh) 2015-01-21
RU2464972C2 (ru) 2012-10-27
RU2008129626A (ru) 2010-01-27
ES2492641T3 (es) 2014-09-10
WO2007071395A1 (en) 2007-06-28
MA30064B1 (fr) 2008-12-01
KR101458728B1 (ko) 2014-11-05
US20200206306A1 (en) 2020-07-02
US20220296675A1 (en) 2022-09-22
ECSP088560A (es) 2008-07-30
TW200803921A (en) 2008-01-16
KR20130024986A (ko) 2013-03-08
PE20071139A1 (es) 2007-11-16
US20090004283A1 (en) 2009-01-01
AU2006328950B2 (en) 2010-07-29
EP3603623A1 (en) 2020-02-05
BRPI0620063B1 (pt) 2020-09-08
AU2006328950A1 (en) 2007-06-28
US20180140662A1 (en) 2018-05-24
KR20140133968A (ko) 2014-11-20
BRPI0620063B8 (pt) 2021-05-25
KR20080078000A (ko) 2008-08-26
TW201424747A (zh) 2014-07-01
CL2018003398A1 (es) 2019-04-26
JP2016216467A (ja) 2016-12-22
EP1968549B1 (en) 2014-05-14
EP2359809A1 (en) 2011-08-24
IL191842A0 (en) 2008-12-29
BR122019027412B8 (pt) 2021-07-27
PL2359809T3 (pl) 2020-01-31
JP6178772B2 (ja) 2017-08-09
CN103251929A (zh) 2013-08-21
PL1968549T3 (pl) 2014-10-31
BR122019027412B1 (pt) 2020-12-01
BRPI0620063A8 (pt) 2018-05-02

Similar Documents

Publication Publication Date Title
AR058591A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido
US11446310B2 (en) Stable formulations for parenteral injection of small molecule drugs
Simon-Yarza et al. Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia
ES2541908T3 (es) Microesferas biodegradables de liberación prolongada y su procedimiento de preparación
ES2185460B1 (es) Microparticula de liberacion prolongada y metodo para su preparacion.
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
JP2010511596A5 (es)
RU2011142843A (ru) Композиция для лечения рака предстательной железы
KR20210055052A (ko) 아미노산 영양소, 및 아미노산 영양소를 포함하는 약제학적 조성물의 적용
JP2012512147A5 (es)
BR112020005948A2 (pt) distribuição intensificada de composições de epinefrina e pró-fármaco
WO2016059592A1 (en) Stable injectable composition of peptide drugs and process for its preparation
HRP20200329T1 (hr) Poboljšane formulacije levosimendana za intravensku primjenu u obliku infuzije ili injekcije i koncentrata infuzije
JP2020510043A5 (es)
US20210161917A1 (en) Composition for subcutaneous injection, containing deoxycholic acid, and preparation method therefor
Long et al. Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetate
US10314880B2 (en) Composition comprising bortezomib
Huang et al. Combined use of borneol or menthol with labrasol promotes penetration of baicalin through rabbit cornea in vitro.
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
CN103908659B (zh) Lhrh类似物和齐考诺肽组合物缓释微球制剂及其制备方法
ES2439497T3 (es) Preparación de una inyección, de una solución para inyección y de un kit de inyección
CN112438942A (zh) 包含碱化剂及其协同物的药物组合物及其应用
BR112020005875A2 (pt) liberação de composições farmacêuticas que incluem intensificadores da permeação
CN101797243B (zh) 一种含有左旋多巴和冰片的组合物及其应用
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)